Gepast gebruik afspraken MammaPrint en Oncotype DX
type: AppropriateUseAgreement
has part: Agreement-0
has part: Agreement-1
has part: Agreement-2
has part: Agreement-3
has part: Agreement-4
has part: {'description': 'Het Zorginstituut zal monitoren en evalueren of er sprake is van gepast gebruik van de testen. In nauwe afstemming met de beroepsgroep worden hiervoor eindpunten gedefinieerd.'}
issued: 2023-09-26

CostEstimation-MammaPrint-Intervention-MammaPrint-Chemo-Additional-default
type: Observation
data set: Kostenraming voor MammaPrint
has cost type: Additional
has intervention: Chemotherapie op basis van MammaPrint uitslag
has number of patients: 808
has timepoint: default
has total costs: -4251723

CostEstimation-MammaPrint-Intervention-MammaPrint-Chemo-Intervention-PostoperativeChemo-Total-default
type: Observation
data set: Kostenraming voor MammaPrint
has cost type: Total
has intervention: Chemotherapie op basis van MammaPrint uitslag
has intervention: Postoperatieve Chemotherapie
has number of patients: 808
has timepoint: default
has total costs: 8521949

CostEstimation-MammaPrint-Intervention-MammaPrint-Substitution-default
type: Observation
data set: Kostenraming voor MammaPrint
has cost type: Substitution
has intervention: Complexe moleculaire diagnostiek genexpressietest op basis van 70 genen, MammaPrint®
has number of patients: 808
has timepoint: default
has total costs: 2625192

CostEstimation-MammaPrint-Intervention-PostoperativeChemo-Current-default
type: Observation
data set: Kostenraming voor MammaPrint
has cost type: Current
has intervention: Postoperatieve Chemotherapie
has number of patients: 808
has timepoint: default
has total costs: 12773672

CostEstimation-MammaPrint-Intervention-PostoperativeChemo-Substitution-default
type: Observation
data set: Kostenraming voor MammaPrint
has cost type: Substitution
has intervention: Postoperatieve Chemotherapie
has number of patients: 373
has timepoint: default
has total costs: 5896757

CostEstimation-OncotypeDX-Intervention-OncotypeDX-Additional-default
type: Observation
data set: Kostenraming voor Oncotype DX
has cost type: Additional
has intervention: Complexe moleculaire diagnostiek genexpressietest op basis van 21 genen, Oncotype DX®
has number of patients: 808
has timepoint: default
has total costs: -2972659

CostEstimation-OncotypeDX-Intervention-OncotypeDX-Chemo-Intervention-PostoperativeChemo-Total-default
type: Observation
data set: Kostenraming voor Oncotype DX
has cost type: Total
has intervention: Chemotherapie op basis van Oncotype DX uitslag
has intervention: Postoperatieve Chemotherapie
has number of patients: 808
has timepoint: default
has total costs: 9801013

CostEstimation-OncotypeDX-Intervention-OncotypeDX-Substitution-default
type: Observation
data set: Kostenraming voor Oncotype DX
has cost type: Substitution
has intervention: Complexe moleculaire diagnostiek genexpressietest op basis van 21 genen, Oncotype DX®
has number of patients: 808
has timepoint: default
has total costs: 3904256

CostEstimation-OncotypeDX-Intervention-PostoperativeChemo-Current-default
type: Observation
data set: Kostenraming voor Oncotype DX
has cost type: Current
has intervention: Postoperatieve Chemotherapie
has number of patients: 808
has timepoint: default
has total costs: 12773672

CostEstimation-OncotypeDX-Intervention-PostoperativeChemo-Substitution-default
type: Observation
data set: Kostenraming voor Oncotype DX
has cost type: Substitution
has intervention: Postoperatieve Chemotherapie
has number of patients: 373
has timepoint: default
has total costs: 5896757

Zorginstituut Nederland
type: FormalOrganization
has unit: Department Zorg I

Distant Relapse-Free Survival
type: Outcome
outcome classification: Survival
outcome measurement: Distant Relapse-Free Survival
is surrogate outcome: true

Invasive Disease-Free Survival
type: Outcome
outcome classification: Survival
outcome measurement: Invasive Disease-Free Survival
is surrogate outcome: true

Standpunt ‘Genexpressietesten bij vrouwen ouder dan 50 jaar en vroeg stadium borstkanker’
type: PackageStatement
contributor: Angèl Link
contributor: Ingrid de Groot
contributor: Steef Redeker
contributor: Yoka Kusumanto
issued: 2023-10-24
publisher: Team Pakket en Advies
has case number: 2022006448
has IIC assessment: IICAssessment-MammaPrint
has IIC assessment: IICAssessment-OncotypeDX
has package type: PointOfView
has serial number: 2022006461
has status: Definitive

TrendAssumption-MammaOnco-default
type: Observation
data set: Geschatte trend voor MammaPrint en/of Oncotype DX
has market penetration: 1
has number of patients: 808
has timepoint: default

Agreement-0
title: {'description': 'Uitgebreide patiëntinformatie en richtlijnen voor professionals over bij welke subgroep van vrouwen deze genexpressietesten van toegevoegde waarde zou kunnen zijn en wat de implicaties zijn, zodat de vrouw in overleg met haar arts een weloverwogen besluit kan nemen of inzet van een genexpressietest in het individuele geval van toegevoegde waarde is (samen beslissen). De BVN heeft toegezegd in afstemming met Patiëntfederatie Nederland de bestaande patiënteninformatie te updaten vóór maart 2024.'}

Agreement-1
title: {'description': 'Revisie van de huidige richtlijn waarin de resultaten van de RxPonder-studie, TailorX-studie (Oncotype DX®) en 8-jaars resultaten van de MINDACT-studie (MammaPrint®) zijn opgenomen. De NABON heeft toegezegd dat de module wordt geprioriteerd voor de volgende jaarlijkse cyclus. Omdat het updaten van richtlijnen niet op korte termijn gerealiseerd is, zal de beroepsgroep een standpunt publiceren over MammaPrint en Oncotype DX op haar website.'}

Agreement-2
title: {'description': 'Inzet van genexpressietesten alleen als add-on-test aan de standaard risicoschatting, indien op basis van de standaard risicoschatting twijfel bestaat over de meerwaarde van adjuvante chemotherapie. Het is niet de bedoeling om de genexpressietest in plaats van de standaard risicoschatting in te zetten.'}

Agreement-3
title: {'description': 'Vanwege het ontbreken van de directe vergelijking weten we nu niet welke test de meeste gezondheidswinst voor de patiënt oplevert. De beroepsgroep spant zich in om hier inzicht in te krijgen door het bijhouden van de internationale literatuur en/of uitkomsten uit registraties. Het Zorginstituut zal jaarlijks navraag doen bij de beroepsgroep of er nieuwe publicaties verschenen zijn.'}

Agreement-4
title: {'description': 'Inzet van één van de testen per tumor (en niet beide testen). Dat de twee testen niet uitwisselbaar zijn zou er mogelijk toe kunnen leiden dat zorgprofessionals en patiënten geneigd zijn om beide testen bij één patiënt af te nemen, om alleen bij concordante uitslagen (dezelfde uitslagen) een patiënt te informeren over het advies over wel of geen adjuvante chemotherapie. Het is echter niet onderzocht of het klinisch nuttig en doelmatig is om beide testen bij één patiënt af te nemen. Het Zorginstituut is daarom van mening dat de inzet van genexpressie testen beperkt moet blijven tot één van de testen per tumor.'}

Budget Impact Analyse voor MammaPrint
type: BIA
has cost estimation: Kostenraming voor MammaPrint
has trend assumption: Geschatte trend voor MammaPrint en/of Oncotype DX

Budget Impact Analyse voor Oncotype DX
type: BIA
has cost estimation: Kostenraming voor Oncotype DX
has trend assumption: Geschatte trend voor MammaPrint en/of Oncotype DX

Stand van de Wetenschap en Praktijk - MammaPrint
type: EMSMP
adheres to EMSMP: true
has PICO: PICO-MammaOnco
has relative effectiveness: Equal
has systematic literature review: Systematisch literatuuronderzoek MammaPrint/Oncotype DX

Stand van de Wetenschap en Praktijk - OncotypeDX
type: EMSMP
adheres to EMSMP: true
has PICO: PICO-MammaOnco
has relative effectiveness: Equal
has systematic literature review: Systematisch literatuuronderzoek MammaPrint/Oncotype DX

IICAssessment-MammaPrint
type: IICAssessment
has assessment type: Reassessment
has BIA: Budget Impact Analyse voor MammaPrint
has conclusion: Positive
has conclusion text: Het Zorginstituut concludeert dat de genexpressietest Oncotype DX® en de genexpressietest MammaPrint® bij de genoemde indicaties voldoet aan ‘de stand van de wetenschap en praktijk’ en daarmee bij deze subgroep van vrouwen vergoed kan worden vanuit de basisverzekering.
has cost effectiveness: CostEffectiveness
  is cost effective: true
has EMSMP: Stand van de Wetenschap en Praktijk - MammaPrint
has intervention: Complexe moleculaire diagnostiek genexpressietest op basis van 70 genen, MammaPrint®

IICAssessment-OncotypeDX
type: IICAssessment
has assessment type: IndicationBroadening
has BIA: Budget Impact Analyse voor Oncotype DX
has conclusion: Positive
has conclusion text: Het Zorginstituut concludeert dat de genexpressietest Oncotype DX® en de genexpressietest MammaPrint® bij de genoemde indicaties voldoet aan ‘de stand van de wetenschap en praktijk’ en daarmee bij deze subgroep van vrouwen vergoed kan worden vanuit de basisverzekering.
has cost effectiveness: CostEffectiveness
  is cost effective: true
has EMSMP: Stand van de Wetenschap en Praktijk - OncotypeDX
has intervention: Complexe moleculaire diagnostiek genexpressietest op basis van 21 genen, Oncotype DX®

Literatuur referentielijst voor MammaPrint en Oncotype DX SLR
type: SystematicLiteratureReview
had member: 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.
had member: 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer
was generated by: Systematisch literatuuronderzoek MammaPrint/Oncotype DX
item list element: 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.
item list element: 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer
number of items: 2

Literatuur zoekopdracht voor RCTs op MammaPrint en Oncotype DX in ICTRP Search Portal (WHO) op 2022-11-01
type: LiteratureSearch
ended at time: 2022-11-01T00:00:00
name: ICTRP Search Portal
query: (mammaprint OR oncotype) AND breast AND (cancer OR carcinoma OR tumor OR tumour OR neoplasm)
target: trialsearch.who.int
has evidence type: OBI_0003699

Literatuur zoekopdracht voor RCTs op MammaPrint en Oncotype DX in Clinicaltrials.gov op 2022-10-26
type: LiteratureSearch
ended at time: 2022-11-01T00:00:00
name: Clinicaltrials.gov
query: (mammaprint OR oncotype) AND breast AND (cancer OR carcinoma OR tumor OR tumour OR neoplasm)
target: clinicaltrials.gov
has evidence type: OBI_0003699

Literatuur zoekopdracht voor RCTs op MammaPrint en Oncotype DX in Cochrane op 2022-11-01
type: LiteratureSearch
ended at time: 2022-11-01T00:00:00
name: Cochrane
query: (mammaprint OR oncotype):ab,ti AND (breast NEXT/2 (cancer OR carcino* OR tumor* OR tumour* OR neoplas*)):ab,ti
target: www.cochranelibrary.com
has evidence type: OBI_0003699

Literatuur zoekopdracht voor MammaPrint en Oncotype DX in Embase op 2022-10-26
type: LiteratureSearch
ended at time: 2022-10-26T00:00:00
name: Embase
query: ((mammaprint* OR 70-gene* OR MINDACT OR oncotype* OR 21-gene*):ab,ti,kw) AND ('breast tumor'/exp OR (((breast*) NEAR/3 (tumor* OR tumour* OR neoplas* OR carcino* OR cancer*))):ab,ti,kw) AND [2018-2023]/py NOT ([Conference Abstract]/lim OR 'editorial'/it OR 'letter'/it OR 'note'/it OR 'chapter'/it OR 'conference abstract'/it OR 'conference paper'/it OR 'conference review'/it OR 'erratum'/it OR [preprint]/lim) NOT ((animal/exp OR animal*:de OR nonhuman/de) NOT ('human'/exp)) AND ('clinical study'/de OR 'clinical trial'/exp OR 'intervention study'/exp OR 'longitudinal study'/exp OR 'prospective study'/exp OR (((clinical OR prospect* OR intervention* OR longitudinal* OR randomi*) NEAR/3 (stud* OR trial*))):ab,ti)
target: www.embase.com

Literatuur zoekopdracht voor MammaPrint en Oncotype DX in Medline op 2022-10-26
type: LiteratureSearch
ended at time: 2022-10-26T00:00:00
name: Medline
query: ((mammaprint* OR 70-gene* OR MINDACT OR oncotype* OR 21-gene*).ab,ti,kf.) AND (exp "Breast Neoplasms"/ OR (((breast*) ADJ3 (tumor* OR tumour* OR neoplas* OR carcino* Or cancer*))).ab,ti,kf.) AND ("Clinical Study".pt OR "Clinical Trial".pt OR "Controlled Clinical Trial".pt. OR "Randomized Controlled Trial".pt. OR "Longitudinal Studies"/ OR "Prospective Studies"/ OR (((clinical OR prospect* OR intervention* OR longitudinal* OR randomi*) ADJ3 (stud* OR trial*))).ab,ti,kf.) NOT ("Editorial".pt. OR "Comment".pt. OR "Letter".pt. OR "News".pt. OR "Congress".pt. OR "Meeting Abstract".pt. OR "Abstracts".pt. OR "Academic Dissertation".pt. OR "Published Erratum".pt. OR (book* OR chapter* OR dissertation abstract*).pt.) NOT (exp animals/ NOT humans/)
target: www.medline.com
has date limit: Interval
  has beginning: Instant
    in XS dg year: 2017
  has end: Instant
    in XS dg year: 2023

Department Zorg I
type: OrganizationalUnit
has unit: Team Pakket en Advies

European Organization For Research And Treatment Of Cancer - Quality Of Life Questionnaire (EORTC QLQ-C30)
type: Outcome
outcome classification: Quality of Life
outcome measurement: European Organization For Research And Treatment Of Cancer - Quality Of Life Questionnaire (EORTC QLQ-C30)
is surrogate outcome: false

EQ-5D-5L - Quality of Life
type: Outcome
outcome classification: Quality of Life
outcome measurement: EQ-5D-5L
is surrogate outcome: false

Functional Assessment of Cancer Therapy - Breast (FACT-B)
type: Outcome
outcome classification: Quality of Life
outcome measurement: Functional Assessment of Cancer Therapy
is surrogate outcome: false

Overall Survival
type: Outcome
outcome classification: Survival
outcome measurement: Overall Survival
is surrogate outcome: false

OutcomeGroup-MammaOnco-10-years
type: OutcomeGroup
endpoint: 10 years or more
outcome: European Organization For Research And Treatment Of Cancer - Quality Of Life Questionnaire (EORTC QLQ-C30)
outcome: EQ-5D-5L - Quality of Life
outcome: Functional Assessment of Cancer Therapy - Breast (FACT-B)
outcome: Overall Survival

OutcomeMeasurement-Distant-Relapse-Free-Survival-ITT-AbsoluteDifference-OncotypeDX
type: STATO_0000614
IAO_0000039: UO_0000187
IAO_0000136: Cohort-RxPONDER-ITT-Comparator
IAO_0000136: Cohort-RxPONDER-ITT-Intervention
IAO_0000221: Distant Relapse-Free Survival
STATO_0000129: 0.1

OutcomeMeasurement-Distant-Relapse-Free-Survival-ITT-HazardRatio-OncotypeDX
type: STATO_0000677
IAO_0000136: Cohort-RxPONDER-ITT-Comparator
IAO_0000136: Cohort-RxPONDER-ITT-Intervention
IAO_0000221: Distant Relapse-Free Survival
STATO_0000129: 1.05

OutcomeMeasurement-Invasive-Disease-Free-Survival-ITT-AbsoluteDifference-OncotypeDX
type: STATO_0000614
IAO_0000039: UO_0000187
IAO_0000136: Cohort-RxPONDER-ITT-Comparator
IAO_0000136: Cohort-RxPONDER-ITT-Intervention
IAO_0000221: Invasive Disease-Free Survival
STATO_0000129: 0.6

OutcomeMeasurement-Invasive-Disease-Free-Survival-ITT-HazardRatio-OncotypeDX
type: STATO_0000677
IAO_0000136: Cohort-RxPONDER-ITT-Comparator
IAO_0000136: Cohort-RxPONDER-ITT-Intervention
IAO_0000221: Invasive Disease-Free Survival
STATO_0000129: 1.04

OutcomeMeasurement-Invasive-Disease-Free-Survival-PP-AbsoluteDifference-OncotypeDX
type: STATO_0000614
IAO_0000039: UO_0000187
IAO_0000136: Cohort-RxPONDER-PP-Comparator
IAO_0000136: Cohort-RxPONDER-PP-Intervention
IAO_0000221: Invasive Disease-Free Survival
STATO_0000129: -0.3

OutcomeMeasurement-Invasive-Disease-Free-Survival-PP-HazardRatio-OncotypeDX
type: STATO_0000677
IAO_0000136: Cohort-RxPONDER-PP-Comparator
IAO_0000136: Cohort-RxPONDER-PP-Intervention
IAO_0000221: Invasive Disease-Free Survival
STATO_0000129: 0.97

OutcomeMeasurement-OverallSurvival-PP-AbsoluteDifference-MammaPrint
type: STATO_0000614
IAO_0000039: UO_0000187
IAO_0000136: Cohort-MINDACT-Comparator
IAO_0000136: Cohort-MINDACT-Intervention
IAO_0000221: Overall Survival
STATO_0000129: 0.3

OutcomeMeasurement-OverallSurvival-PP-HazardRatio-MammaPrint
type: STATO_0000677
IAO_0000136: Cohort-MINDACT-Comparator
IAO_0000136: Cohort-MINDACT-Intervention
IAO_0000221: Overall Survival
STATO_0000129: 1.06

OutcomeMeasurement-OverallSurvival-TTI-AbsoluteDifference-MammaPrint
type: STATO_0000614
IAO_0000039: UO_0000187
IAO_0000136: Cohort-MINDACT-Comparator
IAO_0000136: Cohort-MINDACT-Intervention
IAO_0000221: Overall Survival
STATO_0000129: 1.6

OutcomeMeasurement-OverallSurvival-TTI-HazardRatio-MammaPrint
type: STATO_0000677
IAO_0000136: Cohort-MINDACT-Comparator
IAO_0000136: Cohort-MINDACT-Intervention
IAO_0000221: Overall Survival
STATO_0000129: 1.36

Chemotherapie op basis van Oncotype DX uitslag
type: Intervention
applied intervention: Genetic test adviced Chemotherapy
child intervention: Complexe moleculaire diagnostiek genexpressietest op basis van 21 genen, Oncotype DX®
child intervention: Postoperatieve Chemotherapie
intervention classification: Screening
intervention rationale: Pas chemotherapie toe naar aanleiding van hoge risicoschatting Oncotype DX

70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.
type: JournalArticle

21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer
type: JournalArticle

Team Pakket en Advies
type: OrganizationalUnit

Vrouwen ouder dan 50 met borstkanker, HR+/HER2-, N0, hoog risico op basis van AO! of Predict
type: Population
age: Age more than 50 years
condition: Breast Cancer
condition: Estrogen Receptor Positive Tumor
condition: High risk based on AO! or Predict
condition: Human Epidermal Growth Factor 2 Negative Carcinoma Of Breast
condition: N0 Category
condition: Progesterone Receptor Positive Tumor
sex: Female
treatment: Surgery

Complexe moleculaire diagnostiek genexpressietest op basis van 70 genen, MammaPrint®
type: Intervention
applied intervention: MammaPrint
intervention classification: Screening
intervention rationale: Ondersteunt beslissing om chemotherapie achterwege te laten
has care activity code: 050530
has claim code: 1602
has marketing authorization holder: Agendia

Chemotherapie op basis van MammaPrint uitslag
type: Intervention
applied intervention: Genetic test adviced Chemotherapy
child intervention: Complexe moleculaire diagnostiek genexpressietest op basis van 70 genen, MammaPrint®
child intervention: Postoperatieve Chemotherapie
intervention classification: Screening
intervention rationale: Pas chemotherapie toe naar aanleiding van hoge risicoschatting MammaPrint

Vrouwen ouder dan 50 met borstkanker, HR+/HER2-, N1, hoog risico op basis van AO! of Predict
type: Population
age: Age more than 50 years
condition: Breast Cancer
condition: Estrogen Receptor Positive Tumor
condition: High risk based on AO! or Predict
condition: Human Epidermal Growth Factor 2 Negative Carcinoma Of Breast
condition: N1 Category
condition: Progesterone Receptor Positive Tumor
sex: Female
treatment: Surgery

Systematisch literatuuronderzoek MammaPrint/Oncotype DX
type: SystematicLiteratureReview
has part: Literatuur zoekopdracht voor RCTs op MammaPrint en Oncotype DX in ICTRP Search Portal (WHO) op 2022-11-01
has part: Literatuur zoekopdracht voor RCTs op MammaPrint en Oncotype DX in Clinicaltrials.gov op 2022-10-26
has part: Literatuur zoekopdracht voor RCTs op MammaPrint en Oncotype DX in Cochrane op 2022-11-01
has part: Literatuur zoekopdracht voor MammaPrint en Oncotype DX in Embase op 2022-10-26
has part: Literatuur zoekopdracht voor MammaPrint en Oncotype DX in Medline op 2022-10-26
result: Literatuur referentielijst voor MammaPrint en Oncotype DX SLR

Substitutie scenario voor MammaPrint en/of Oncotype DX
type: Scenario
description: Dit scenario beschrijft de substitutie van standaardzorg door MammaPrint & Oncotype tests.

Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes (MINDACT)
type: OBI_0003699
source: Clinicaltrials.gov

Complexe moleculaire diagnostiek genexpressietest op basis van 21 genen, Oncotype DX®
type: Intervention
applied intervention: OncotypeDX
intervention classification: Screening
intervention rationale: Ondersteunt beslissing om chemotherapie achterwege te laten
has care activity code: 050531
has claim code: 2601
has marketing authorization holder: Exact Sciences

Geschatte trend voor MammaPrint en/of Oncotype DX
type: DataSet
has scenario: Substitutie scenario voor MammaPrint en/of Oncotype DX

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
type: OBI_0003699
source: Clinicaltrials.gov

Kostenraming voor MammaPrint
type: DataSet
has scenario: Substitutie scenario voor MammaPrint en/of Oncotype DX

Kostenraming voor Oncotype DX
type: DataSet
has scenario: Substitutie scenario voor MammaPrint en/of Oncotype DX

Postoperatieve Chemotherapie
type: Intervention
applied intervention: Postoperative chemotherapy
intervention classification: Pharmacological Interventions
intervention rationale: behandeling van afstandsmetastasen na chirurgie

STATO_0000196
BFO_0000051: STATO_0000314
  STATO_0000129: 2.5
BFO_0000051: STATO_0000315
  STATO_0000129: 0.74
IAO_0000136: OutcomeMeasurement-OverallSurvival-TTI-HazardRatio-MammaPrint

STATO_0000196
BFO_0000051: STATO_0000315
  STATO_0000129: -1.3
BFO_0000051: STATO_0000314
  STATO_0000129: 2.0
IAO_0000136: OutcomeMeasurement-Invasive-Disease-Free-Survival-ITT-AbsoluteDifference-OncotypeDX

STATO_0000196
BFO_0000051: STATO_0000315
  STATO_0000129: 0.81
BFO_0000051: STATO_0000314
  STATO_0000129: 1.37
IAO_0000136: OutcomeMeasurement-Distant-Relapse-Free-Survival-ITT-HazardRatio-OncotypeDX

STATO_0000196
BFO_0000051: STATO_0000315
  STATO_0000129: -2.96
BFO_0000051: STATO_0000314
  STATO_0000129: 3.52
IAO_0000136: OutcomeMeasurement-OverallSurvival-PP-AbsoluteDifference-MammaPrint

STATO_0000196
BFO_0000051: STATO_0000314
  STATO_0000129: 2.3
BFO_0000051: STATO_0000315
  STATO_0000129: -2.0
IAO_0000136: OutcomeMeasurement-Invasive-Disease-Free-Survival-PP-AbsoluteDifference-OncotypeDX

STATO_0000196
BFO_0000051: STATO_0000315
  STATO_0000129: 1.47
BFO_0000051: STATO_0000314
  STATO_0000129: 4.73
IAO_0000136: OutcomeMeasurement-OverallSurvival-TTI-AbsoluteDifference-MammaPrint

STATO_0000196
BFO_0000051: STATO_0000315
  STATO_0000129: -0.8
BFO_0000051: STATO_0000314
  STATO_0000129: 1.7
IAO_0000136: OutcomeMeasurement-Distant-Relapse-Free-Survival-ITT-AbsoluteDifference-OncotypeDX

STATO_0000196
BFO_0000051: STATO_0000314
  STATO_0000129: 1.22
BFO_0000051: STATO_0000315
  STATO_0000129: 0.77
IAO_0000136: OutcomeMeasurement-Invasive-Disease-Free-Survival-PP-HazardRatio-OncotypeDX

STATO_0000196
BFO_0000051: STATO_0000314
  STATO_0000129: 1.3
BFO_0000051: STATO_0000315
  STATO_0000129: 0.8
IAO_0000136: OutcomeMeasurement-Invasive-Disease-Free-Survival-ITT-HazardRatio-OncotypeDX

STATO_0000196
BFO_0000051: STATO_0000314
  STATO_0000129: 2.13
BFO_0000051: STATO_0000315
  STATO_0000129: 0.53
IAO_0000136: OutcomeMeasurement-OverallSurvival-PP-HazardRatio-MammaPrint